Neville Rodie & Shaw Inc. Has $13.23 Million Position in Eli Lilly and Company (NYSE:LLY)

Neville Rodie & Shaw Inc. lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,934 shares of the company’s stock after selling 439 shares during the period. Neville Rodie & Shaw Inc.’s holdings in Eli Lilly and Company were worth $13,230,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of LLY. Swedbank AB acquired a new stake in Eli Lilly and Company during the first quarter worth $932,797,000. Vanguard Group Inc. boosted its stake in Eli Lilly and Company by 1.6% during the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after buying an additional 1,133,810 shares in the last quarter. Wulff Hansen & CO. boosted its stake in Eli Lilly and Company by 90,438.0% during the second quarter. Wulff Hansen & CO. now owns 937,068 shares of the company’s stock worth $848,403,000 after buying an additional 936,033 shares in the last quarter. GQG Partners LLC boosted its stake in shares of Eli Lilly and Company by 20.2% in the 1st quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock valued at $2,994,280,000 after purchasing an additional 648,094 shares in the last quarter. Finally, Comerica Bank boosted its stake in shares of Eli Lilly and Company by 71.6% in the 2nd quarter. Comerica Bank now owns 1,512,983 shares of the company’s stock valued at $1,369,825,000 after purchasing an additional 631,312 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $891.01 on Thursday. The company has a market cap of $846.82 billion, a PE ratio of 131.22, a PEG ratio of 2.78 and a beta of 0.42. The company’s 50-day moving average is $897.24 and its two-hundred day moving average is $846.22. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Equities analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on LLY shares. Berenberg Bank boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Truist Financial restated a “buy” rating and issued a $1,000.00 target price (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Finally, Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $977.35.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 93,593 shares of the stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $918.64, for a total value of $85,978,273.52. Following the sale, the insider now directly owns 97,153,810 shares in the company, valued at approximately $89,249,376,018.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 355,962 shares of company stock worth $331,267,535 in the last ninety days. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.